Project CAR-T Cell Therapy

Revolutionizing Cancer Treatment with Precision Immunotherapy

Project Adoptive T Cell Therapy

Defeating Infections Post-Transplant, One Cell at a Time

Project CAR-NK Cell Therapy

Unleashing Natural Killer Cells for Targeted Cancer Therapy

Project CAR-M Cell Therapy

Crafting Prototypes for Next-Generation Immuno-Oncology

Project MSC Cell Bank and Exosome Therapy

Harnessing Nature's Healing Power for Disease Treatment

Research Horizons

Charting the Path to Tomorrow's Healthcare Solutions with CRISPR, mRNA, and Advanced Pharmaceuticals

Projects Overview: Transforming Healthcare Through Innovative Biotechnological Solutions

General Description:

Pioneera Biosciences is committed to advancing healthcare through a range of cutting-edge projects aimed at delivering accessible and effective therapeutic solutions. Our projects span diverse areas, from pioneering cell therapies like CAR-T and CAR-NK to developing advanced pharmaceutical technologies and strategic molecules. We are also focused on early cancer detection through an innovative IVD platform aligned with our broader goals.


Scientific Focus:

Our targeted products include CAR-T cell therapy, designed for the treatment of AML, ALL, and Multiple Myeloma, with successful animal model development and proof of concept in transfection techniques. We've also achieved milestones in Adoptive T Cell Therapy, demonstrating efficacy in preventing CMV infection in post-transplant patients. Our ongoing research includes CAR-NK and NK cell therapy, CAR-M cell therapy with library studies underway, and MSC cell bank and exosome therapy for targeted disease treatment.


Professional Achievement:

As a leading biotechnology company, we're positioned at the forefront of scientific innovation. Our research and development horizon encompass CRISPR and mRNA-based products, advanced biological solutions such as peptides, monoclonal antibodies, and vaccines, and advanced pharmaceutical technologies like new drug delivery systems (LNP, Implants) and therapeutic strategies utilizing exosomes. Furthermore, our focus on developing new pharmaceutical products, including strategic molecules recently introduced to the global market, highlights our commitment to driving impactful change in healthcare.


In addition to these achievements, our dedication to early cancer detection is reflected in our IVD platform, demonstrating our holistic approach to improving patient outcomes and advancing the field of biotechnology.